Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA for \>= 3 months.~* Subjects must have been on oral or parenteral MTX therapy \>= 3 months and on a stable dose for \>= 4 weeks prior to first dose of study drug.~* Must have discontinued all conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (other than MTX) \>= 4 weeks prior to first dose of study drug.~* Meets the following minimum disease activity criteria: \>= 6 swollen joints (based on 66 joint counts) and \>= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.~Exclusion Criteria:~* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).~* Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).~* Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.
- Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.
- Methotrexate / Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.
- Methotrexate / Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.

Based on this trial design, predict the completion outcome and termination type (if applicable).